Immutep Collaborates With Merck To Evaluate Efti In Combination Therapy For Metastatic NSCLC
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Immutep Limited (IMMP,IMM.AX) said that it has reached a clinical trial collaboration and supply agreement with Merck & Co., Inc. (MRK) to evaluate eftilagimod alfa (efti) in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab) and chemotherapy for the
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1483251775-fc4e2465da414b9ebc9344113de8a590.jpg "How Health Care Is Moving Toward Blockchain")
:max_bytes(150000):strip_icc():format(jpeg)/paperwork-4596472be17e44b691fc63ab4caa74a4.jpg "<div>Taxable Income vs. Gross Income: What's the Difference?</div>")
